Insulet Stock - Friday sector check and weekly review
19.06.2026 - 20:49:50 | ad-hoc-news.de
Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 20:45 CET. Details in the imprint.
Insulet (US45784P1012) ends the week without a fresh Investor Relations statement or major wire report on Friday. With no new earnings updates or filings from the diabetes-technology specialist, the focus shifts to its sector backdrop and how the shares have fared over the week.
All news and data on Insulet stock
For a broader view of Insulet’s equity story, historical news and key figures, our topic page compiles recent headlines and core market data in one place.
Week closes without fresh filings
A review of Insulet’s Investor Relations website on Friday shows no new press releases or SEC filing links beyond previously known updates from earlier in the month. The company’s latest detailed communication remains its earlier quarterly and presentation material on the site.
Major international business wires such as Reuters and Bloomberg also did not carry a new Insulet-specific headline on Friday, underscoring that the company has had a quiet news day from a corporate-disclosure perspective compared with some larger healthcare peers.
How Insulet sits in its sector
Insulet operates in the wider diabetes-care and medical technology space, alongside larger diversified device makers and insulin-pump rivals that also serve type 1 and type 2 patients. These peers include glucose-monitoring specialists and broader medtech groups with exposure to cardiology and surgical devices.
Investor attention in the sector in recent months has often centered on how GLP-1 obesity and diabetes drugs could affect device demand, leading to periods of volatility for diabetes-technology stocks as markets reassess long-term growth assumptions relative to pharmaceutical alternatives.
The product behind the stock
Insulet generates most of its revenue from its Omnipod insulin management system, a tubeless patch pump worn on the body that delivers insulin continuously and can be controlled by a handheld device or compatible controller. The system targets people with insulin-dependent diabetes seeking an alternative to multiple daily injections.
Where the stock trades today
Insulet shares (US45784P1012) last traded on Nasdaq at $128.05 as of 06/19/2026, 20:00 CET, based on recent delayed quote data in USD.
Key facts on Insulet stock
- Company: Insulet Corp.
- ISIN: US45784P1012
- WKN: A0YCM0
- Ticker: PODD
- Venue: Nasdaq
- Price (as of 06/19/2026, 20:00 CET): 128.05 USD
- Market cap: 8,300,000,000 USD (as of 06/19/2026)
- Sector / Industry: Health Care / Medical Technology
- Index membership: Standard & Poor's 500 index
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
